ICAM1 and COVID-19: During hospitalization, s-ICAM-1 concentrations only showed a significant reduction in severe COVID-19 patients at days 3–4 (P < 0.001 vs. Admission), remaining unchanged in both groups of critically ill patients (Fig. 3A–C).